Medication Dosing:
Children vs Adults
— Calculation Guide
A comprehensive clinical reference covering weight-based, BSA, and age-based dosing formulas, physiological differences, and practical safety checks for healthcare professionals.
Children are not small adults. This foundational principle of pediatric pharmacology drives every dosing decision in clinical practice. Drug absorption, distribution, metabolism, and excretion (ADME) differ dramatically across age groups — meaning that a straightforward milligram-for-milligram dose reduction is rarely appropriate and can be genuinely dangerous.
This guide walks through the major dosing methodologies, the physiological rationale behind each, and the formulas clinicians rely on daily — from neonatal ICUs to adult care wards.
Why Dosing Differs: Physiological Basis
The differences between pediatric and adult pharmacokinetics stem from ongoing organ development, changing body composition, and maturing enzyme systems. Understanding these differences is prerequisite to safe dose calculation.
👶 Pediatric Factors
- Higher total body water (75–80% in neonates vs ~60% in adults)
- Lower plasma protein binding (albumin and α₁-AGP immature)
- Immature hepatic CYP enzyme systems
- Lower GFR; renal maturity reached ~1–2 years
- Faster metabolic rate per kg body weight
- Greater GI permeability (neonates)
- Thinner skin → enhanced transdermal absorption
🧑 Adult Considerations
- Stable organ function (unless comorbidities)
- Predictable volume of distribution
- Mature CYP450 enzymes (subject to induction/inhibition)
- Standard hepatic first-pass effect
- Renal function declines with age (>65 yrs)
- Increased adipose in elderly → altered Vd for lipophilic drugs
- Polypharmacy risk in geriatrics
Pediatric Dosing Methods
1 · Weight-Based Dosing (mg/kg)
The most widely used and recommended approach for children. The prescriber selects a dose in mg per kilogram of body weight from reference guidelines, then multiplies by the child’s actual body weight.
Child Dose (mg) = Dose (mg/kg) × Weight (kg)
2 · Body Surface Area Method (BSA)
BSA correlates better than weight alone with many pharmacokinetic parameters (cardiac output, GFR, metabolic rate). It is the preferred method for chemotherapy agents, some immunosuppressants, and drugs with narrow therapeutic windows.
BSA (m²) = √[ (Height(cm) × Weight(kg)) / 3600 ]
Child Dose = Adult Dose × (Child BSA / 1.73 m²)
3 · Age-Based Rules (Historical / Approximation Only)
Older formulas based purely on age are now considered imprecise and potentially unsafe. They are presented here for historical context and basic understanding only.
| Rule | Formula | Basis | Accuracy |
|---|---|---|---|
| Young’s Rule | Age / (Age + 12) × Adult Dose |
Age (years) | Limited |
| Clark’s Rule | Weight(lb) / 150 × Adult Dose |
Weight (lb) | Moderate |
| Fried’s Rule | Age(months) / 150 × Adult Dose |
Infants <2 yr | Rough estimate |
| Cowling’s Rule | (Age + 1) / 24 × Adult Dose |
Age (years) | Limited |
Adult Dosing Calculations
In adults, the focus shifts from developmental physiology to organ function, renal/hepatic impairment, and pharmacogenomics. Standard adult doses assume normal organ function in a reference 70 kg patient.
Creatinine Clearance (Renal Adjustment)
Renally cleared drugs require dose adjustment in renal impairment. The Cockcroft-Gault equation remains the most widely used estimate of creatinine clearance (CrCl) in clinical practice.
CrCl (mL/min) = [(140 − Age) × Weight(kg)] / [72 × SCr(mg/dL)]
Hepatic Impairment (Child-Pugh Score)
For drugs with significant hepatic first-pass metabolism, the Child-Pugh classification guides dose reduction:
| Child-Pugh Class | Score | Hepatic Function | Typical Dose Adjustment |
|---|---|---|---|
| Class A | 5–6 points | Well-compensated | No change |
| Class B | 7–9 points | Significant compromise | Reduce 25–50% |
| Class C | 10–15 points | Decompensated | Avoid / >50% reduction |
Loading vs Maintenance Doses
LD = Vd (L/kg) × Weight (kg) × Target Concentration (mg/L)
MD = CL (L/hr) × Target Concentration (mg/L) × Dosing Interval (hr)
Side-by-Side Comparison
| Parameter | Pediatric | Adult | Key Implication |
|---|---|---|---|
| Primary basis | mg/kg or BSA | Fixed dose or mg/kg | Always weigh child; never estimate |
| Volume of distribution | Higher (↑TBW) | Lower relative TBW | Higher mg/kg doses often needed |
| Hepatic metabolism | Immature → slower (neonates), faster (toddlers) | Mature CYP450 | Dosing frequency varies by age |
| Renal clearance | Low at birth; adult levels by ~2 years | Declines after age 40–50 | Adjust dose in neonates and elderly |
| Protein binding | Reduced (↑ free drug) | Normal or drug-dependent | Risk of toxicity at normal doses |
| Maximum dose cap | Always apply adult max | Per monograph | Prevent overdose in large children |
| Formulation | Liquids, dispersibles preferred | Tablets, capsules | Palatability and accuracy critical |
Step-by-Step: Safe Pediatric Dose Calculation
-
1Obtain accurate weight Weigh the child in kilograms immediately before prescribing. Never use estimated or reported weights for high-risk drugs. For neonates, record weight in grams.
-
2Confirm the recommended dose range Consult a validated reference (BNFc, Lexicomp Pediatrics, or Micromedex NeoFax). Note both the minimum and maximum recommended dose in mg/kg.
-
3Calculate and apply the adult maximum cap Multiply: dose (mg/kg) × weight (kg). Then compare with the maximum adult dose. Never exceed the adult maximum even if the weight-based calculation suggests a higher amount.
-
4Select appropriate formulation and concentration Confirm the available liquid concentration (e.g., 250 mg/5 mL). Calculate volume to dispense: Volume (mL) = Dose (mg) ÷ Concentration (mg/mL).
-
5Independent double-check For all high-alert medications (opioids, electrolytes, insulin, anticoagulants), a second clinician must independently verify the calculation before administration.
-
6Document and monitor Record the dose, weight used, and rationale. Monitor for therapeutic response and adverse effects. Adjust at follow-up visits as the child’s weight changes.
Common High-Risk Drug Examples
| Drug | Pediatric Dose | Adult Dose | Special Notes |
|---|---|---|---|
| Paracetamol | 10–15 mg/kg/dose Q4–6h Max 60 mg/kg/day |
500–1000 mg Q4–6h Max 4 g/day |
Hepatotoxicity risk with overdose; avoid in neonates <32 wks without specialist advice |
| Amoxicillin | 25–45 mg/kg/day ÷ Q8h Max 90 mg/kg/day |
500 mg–1 g TID | High-dose for AOM; ensure renal dose adjustment in impairment |
| Ibuprofen | 5–10 mg/kg/dose Q6–8h Age ≥3 months only |
200–800 mg Q6–8h Max 3.2 g/day |
Avoid in renal impairment, dehydration, and <3 months of age |
| Morphine | 0.1–0.2 mg/kg IV/SC Q4h High-alert |
2.5–10 mg IV/SC Q4h | Neonates highly sensitive; use with caution <1 month; always have naloxone available |
| Vancomycin | 15 mg/kg IV Q6h (neonates Q8–12h) | 15–20 mg/kg Q8–12h | TDM mandatory; adjust per AUC/MIC (ASHP/IDSA 2020 guidelines) |
Special Populations & Considerations
Neonates (0–28 days)
The highest-risk group due to immature organ function, limited data, and rapid physiological change. Key concerns include:
- Glucuronidation pathway immature — avoid drugs relying on it (e.g., chloramphenicol → grey baby syndrome)
- Blood-brain barrier more permeable → CNS drug effects amplified
- Drug interactions with kernicterus risk in jaundiced infants (bilirubin displacement)
- Extremely narrow therapeutic windows; TDM essential
Elderly Adults (>65 years)
Age-related decline in organ function mirrors, in some ways, the immaturity seen in neonates — albeit through degeneration rather than development:
- Reduced renal function: apply Cockcroft-Gault with actual or adjusted body weight
- Reduced hepatic mass and blood flow → reduced first-pass metabolism
- Increased fat:lean ratio → prolonged t½ of lipophilic drugs (e.g., diazepam)
- Decreased albumin → increased free fraction of highly bound drugs
- Start low, go slow principle: initiate at 50% of standard adult dose and titrate
Key Safety Principles Summary
- Always weigh before prescribing — never estimate for high-risk drugs
- Apply the adult dose ceiling — weight-based calculations in large children must not exceed standard adult doses
- Use age-appropriate references — general formularies are not substitutes for BNFc or Lexicomp Pediatrics
- Perform independent double-checks on all high-alert medications
- Adjust for organ impairment — renal and hepatic function must be assessed in both children and adults
- Consider developmental pharmacology — enzyme maturation profoundly affects dosing in the first two years of life
- Reassess at every visit — children’s doses must be recalculated as they grow
References & Further Reading
- British National Formulary for Children (BNFc). Pharmaceutical Press, 2024–2025 edition.
- Kearns GL et al. Developmental pharmacology — drug disposition, action, and therapy in infants and children. NEJM. 2003;349(12):1157–1167.
- Micromedex NeoFax & Pediatrics (Truven Health Analytics). Accessed April 2026.
- Rybak MJ et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis. 2020;71(6):1361–1364.
- World Health Organization. WHO Model Formulary for Children. Geneva: WHO, 2023.
Leave a Reply